GENERAL COMMENTS
1. In the ongoing ChiOTEAF Registry study, the aims are to explore contemporary antithrombotic strategies amongst the Chinese elderly population in the new era of non-vitamin K antagonist oral anticoagulants (NOACs), and secondly, to compare the clinical characteristics and outcomes between the Chinese and European AF populations. However, in the methods section it indicates that the present registry will recruit 5000 AF patients aged over 50 years old in China. Most developed world countries have accepted the chronological age of 65 years as a definition of 'elderly' or older person. Why in the present registry the authors defined age over 50 years as elderly? Patients with a younger age compared with those real elderly patients have a significantly lower risk of thromboembolism and bleeding. 2. In Table 1 (Clinical epidemiology of atrial fibrillation in China), the recently published paper entitled "The prevalence, incidence, management and risks of atrial fibrillation in an elderly Chinese population: a prospective study" can be added into table 1.
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GENERAL COMMENTS
Dear Authors, It is with pleasure I read your protocol but, although I believe you will eventually achieve an interesting observational trial, I don't believe that the present protocol is ready for publication now. Please let me address a few points that might be useful for future submissions.
1-The text needs a full revision to improve the written English, to make the verbal tenses uniform, to correct the typos and to delete repetition.
2-Your focus on the elderly is in contrast with the age cut off you chose, 50 years old. Please choose an higher cut off or, better, specify that the analysis will be conducted for age groups, and particularly for patients >=75y.
3-It would be nice to add a flow chart of the study Reply： Many thanks for the comment, we revised the age cut-off point to 65 years old.
2. In Table 1 (Clinical epidemiology of atrial fibrillation in China), the recently published paper entitled "The prevalence, incidence, management and risks of atrial fibrillation in an elderly Chinese population: a prospective study" can be added into table 1. Reply: Added the reference 36, and added into Dear Authors, It is with pleasure I read your protocol but, although I believe you will eventually achieve an interesting observational trial, I don't believe that the present protocol is ready for publication now. Please let me address a few points that might be useful for future submissions.
1-The text needs a full revision to improve the written English, to make the verbal tenses uniform, to correct the typos and to delete repetition. Reply: Thanks for the comment, we revised it as we tried.
Reply: We added "the analysis will be conducted for age groups, particularly for patients>=75y…" into the "Statistical approach", please see the third paragraph, page 8, thanks.
3-It would be nice to add a flow chart of the study Reply: Added the flow chart, please see page 28. Table 1 , Clinical events includes the thromboembolism, haemorrhage, acute coronary syndrome (ACS), and all-cause death, which have been descripted more detail as required. Actually, the liver function has been collected in this registry, which has been added into Table 1 . To collect the lipid profile laboratory values is to observe atherosclerotic clinical risk profile, which is common in elderly population with AF. Thanks. Tables 2 and 3 are too informative and beyond the purposes of the protocol. Please reduce the text or leave for the appendix Reply: The differences in AF management can be compared and analyzed in Western and Chinese populations, which is the main objective of the present study. 
5-
GENERAL COMMENTS
Compared with previous version, this manuscript had been improved significantly. However, in the Figure 1 Flowing chart, the sentence "Recruit 5000 AF patients aged over 50 years" is still needed to be revised. And I am still concerned about what kind of patients (>50 years or >65 years) had been enrolled in the present study because the enrollment will be ended in this year. The authors do not have sufficient time to adjust the protocol according to my understanding.
REVIEWER
Serena Granziera
Medicina Fisica e Riabilitativa, Villa Salus, Italy REVIEW RETURNED 17-Nov-2017 Table 2 and 3 are too large and beyond the purposes of the study 6-Ok, thank you 7-Ok 8-I was actually suggesting to add some data regarding the pilot study results. Compared with previous version, this manuscript had been improved significantly. However, in the Figure 1 Flowing chart, the sentence "Recruit 5000 AF patients aged over 50 years" is still needed to be revised. And I am still concerned about what kind of patients (>50 years or >65 years) had been enrolled in the present study because the enrollment will be ended in this year. The authors do not have sufficient time to adjust the protocol according to my understanding.
GENERAL COMMENTS
VERSION 2 -AUTHOR RESPONSE
Response: Thank you. We have changed Figure 1 . The present prospective cohort study aims to explore contemporary antithrombotic strategies among the Chinese elderly population in the new era of non-vitamin K antagonist oral anticoagulants (NOACs). We have communicated with research centers to recruit the general elderly population with AF.
As shown in the determination of sample size, the sample size for this study was at least 1,554 patients with one-year of follow-up to show a crude difference with anticoagulant use based on our previous study (an annual rate of stroke/systemic thromboembolism of 6.0% in the nonanticoagulated AF population compared to 2.0% in anticoagulated patients (Guo Y, et al. Int J Cardiol. 2013) and the withdrawal rate of 10%. However, since the present study is an observational study, patients will be enrolled as soon as possible as in the real-world situation, and we estimated that we will need a sample size of 5,000 cases.
In fact, most of patients have been enrolled in the Department of Geriatric Cardiology in the present study. Up to August 2017, we have recruited over 6,000 patients, and about 85% of the patients (5,100 patients) are over 65 years of age, so we have already achieved the estimated sample size of 5,000 patients. There is the enough power to do the subgroup analysis we preplanned. Moreover, we will further perform the subgroup analysis by age to explore the association between anticoagulant therapy and clinical adverse outcomes. 4-In addition, please add the complete blood count Response: Thank you. We added the complete blood count as required. Please see Table 1 on  page17. 5-I still believe Table 2 and 3 are too large and beyond the purposes of the study Response: Thank you. Tables 2 and 3 reviewed the main studies involving the Chinese population to show the disparity of clinical epidemiology between Chinese and Western populations to explain why the ChiOTEAF registry would provide insight into the treatment gap of AF management that exists between Western and Eastern populations.
6-Ok, thank you Response: Thank you.
7-Ok
Response: Thank you.
8-I was actually suggesting to add some data regarding the pilot study results. Response: Thank you. We have added the pilot investigation data. Please see the last paragraph on page 7 and the first paragraph on page 8. "A pilot investigation was initially carried out to obtain general information on the rate of AF patients by age in the possible sites before the full ChiOTREAF registry commended. The investigation showed that the distribution rates of AF were about 15%, 18%, 44%, and 23% in the age groups of 50-64 years, 65-74 years, 75-84 years, and aged over 85 years, respectively."
Editorial Comments and Requests:
Please note that we normally allow a maximum of two manuscript revisions. As such, we urge you to make all the necessary revisions at this stage in an effort to convince the reviewers and editorial team that your work is suitable for publication in BMJ Open.
We agree with reviewer 1's concerns about the revision to the age of the patients analysed. You have previously stated that you are at the end of the data collection phase for this study so can you elaborate on how you have been able to incorporate this change into the protocol? Will this change how you analyse the data? Will your study be adequately powered with this change to the inclusion criteria? You say on page 9 that a sample size of 5,000 enrolled patients would be needed. Response: Thank you. The present prospective cohort study aims to explore contemporary antithrombotic strategies among the elderly Chinese population in the new era of non-vitamin K antagonist oral anticoagulants (NOACs). We have communicated with research centers to recruit the general elderly population with AF.
As shown in the determination of sample size, the sample size for this study will be at least 1,554 patients with one-year follow-up to show a crude difference with anticoagulant use based on our previous study (an annual rate of stroke/systemic thromboembolism of 6.0% in the nonanticoagulated AF population compared to 2.0% in anticoagulated patients (Guo Y, et al. Int J Cardiol. 2013) and the withdrawal rate of 10%. However, since the present study is an observational study, patients will be enrolled as soon as possible as in the real-world situation, and we estimated that we will need a sample size of 5,000 cases.
In fact, most of the patients in the Department of Geriatric Cardiology have been enrolled in the present study. Up to August 2017, we have recruited over 6,000 patients, and about 85% of the patients (5,100 patients) are over 65 years of age, so we have already achieved the estimated sample size of 5,000 patients. There is the enough power to do the subgroup analysis we preplanned.
